The global 3 phosphoinositide dependent protein kinase 1 market is anticipated to grow at a significant CAGR during the forecast period. Rise in inclination towards the adoption of various strategic initiative such as product expansion, mergers and acquisitions, partnerships, collaborations, and geographical expansion is the major factor contributing to the growth of the market. For instance, in September 2020, Gilead Sciences, Inc. and Immunomedics entered into a definitive agreement pursuant to which Gilead acquired Immunomedics for $88 per share in cash.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/3-phosphoinositide-dependent-protein-kinase-1-market
The transaction, which values Immunomedics at approximately $21 billion, was unanimously approved by both the Gilead and Immunomedics Board of Directors and closed during the fourth quarter of 2020. The agreement provided Gilead with Trodelvy, a first-in-class Trop-2 directed antibody-drug conjugate (ADC) that was granted and approved by the USFDA in April for the treatment of adult patients with metastatic triple-negative breast cancer (mTNBC) with two prior therapies for metastatic disease.
Additionally, in June 2019, Amgen Inc. and Allergan PLC received an approval from the USFDA for KANJINTI. It has been approved for all indications of the reference product, Herceptin for the treatment of HER2-overexpressing adjuvant and metastatic breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.
Market Coverage
- The market number available for – 2021-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered-
o By Drug Type
o By Distribution Channel
- Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
- Competitive Landscape – including, Boehringer Ingelheim GmbH, AstraZeneca PLC, Arno Therapeutics Inc., Sanofi SA, Novartis International AG, and others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How has COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
- Who is the leader in the market?
- How are players addressing challenges to sustain growth?
- Where is the investment opportunity?
Global 3 Phosphoinositide Dependent Protein Kinase 1 Market Report Segment
By Drug Type
- HCI-1708
- AR-12
- PHT-427
- SNS-229
- Others
By Application
- Hospitals
- Clinics
- Others
A full report of 3 Phosphoinositide Dependent Protein Kinase 1 Market is available at: https://www.omrglobal.com/industry-reports/3-phosphoinositide-dependent-protein-kinase-1-market
3 Phosphoinositide Dependent Protein Kinase 1 Market– Segment by Region
North America
- United States
- Canada
Europe
- Germany
- United Kingdom
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
Rest of the World
- Middle East & Africa
- Latin America
Company Profiles
- Arno Therapeutics Inc.
- AstraZeneca PLC
- Bayer AG
- Boehringer Ingelheim GmbH
- Novartis International AG
- Pfizer Inc.
- Sanofi SA
- Sunesis Pharmaceuticals Inc.
- Tolero Pharmaceuticals Inc.
